MYB binds more than ten thousand promoters in cancer cells and regulates genes involved in cell cycle [cyclins and cyclin-dependent kinases (CDKs)] and cell death [survivin (BIRC5), B-cell lymphoma 2 (BCL2), ataxia telangiectasia and Rad3 related protein (ATR)], as well as protein kinases [insulin-like growth factor 1 receptor (IGF-1R), KIT, polo-like kinase 1 (PLK1)] and growth factors [vascular endothelial growth factor (VEGF)][10,19]. This evidence concerns the gene PLK1 and cancer.